The FDA granted accelerated approval to Boehringer Ingelheim’s oral targeted therapy zongertinib for patients with non-small cell lung cancer harboring specific HER2 mutations. The approval provides a less invasive treatment option that improves safety profiles compared to existing therapies. This milestone underscores growing precision oncology efforts to expand options for oncogene-driven lung cancers, and is expected to enhance patient outcomes by catering to this molecular subset.